Adverum Biotechnologies announces new data from OPTIC Phase 1 trial

Adverum Biotechnologies announces new data from OPTIC Phase 1 trial

Date: 2020-02-10 By Pankaj Singh

Adverum Biotechnologies, a California based biotech company, has reportedly announced new clinical data from the OPTIC Phase 1 with dose ranging clinical stage trial of gene therapy intravitreal injection namely ADVM-022....

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, be....

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced ....

Premier to buy two Greater New York Hospital Association subsidiaries

Premier Inc., a renowned healthcare improvement company, has reportedly announced that it has entered a definitive agreement to purchase certain liabilities and all the assets of Nexera, Inc. and Acurity, Inc., two wholly owned indirect sub....

Mitsubishi creates new technology to control in-building mobile robots

Mitsubishi Electric Corporation has recently announced its technological development to control in-building mobile robots, by using building dynamic maps. This new 3D building map will show the status of mobilities within the building, incl....

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administra....

Cerevel Therapeutics begins CVL-936 trial for treating drug addiction

Cerevel Therapeutics, LLC, a biopharmaceutical company developing new therapies for treating neuroscience diseases, has reportedly dosed healthy volunteers in Phase 1 clinical trial of CVL-936, a potential first-in-class investigational the....